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Glycogen synthase kinase-3 (GSK-3) is an important immune regulator that controls inflammation 
via inhibition of its protein kinase activities. Persistent inflammatory responses through the 
activation of immune cells and excessive production of immune mediators may cause tissue 
destruction and implicated in the development of chronic inflammatory diseases. The objective of 
this study was to examine the role of Tideglusib, a GSK-3 inhibitor, in inflammatory responses 
elicited through macrophage activation by investigating the expression of cell surface biomarkers 
and inflammatory molecule levels. Method: The effects of GSK-3 inhibition by Tideglusib on the 
expression of CD11b and CD40 and secretion of pro-inflammatory cytokines in the 
lipopolysaccharide (LPS)-activated macrophage-derived RAW 264.7 cells were determined by 
flow cytometry, while the presence of nitric oxide (NO) was determined by Griess assay. Results: 
Stimulation of RAW 264.7 cells with LPS increased substantial levels of CD11b and CD40 
expressions, and secretion of NO, TNF-α, and MCP-1. However, the expression of these molecules 
was suppressed through inhibition of GSK-3. Conclusion: These findings suggest the significant 
role of Tideglusib to limit the upregulation of immune responses in activated macrophages, and as 
a potential anti-inflammatory drug for the intervention and treatment of inflammatory diseases. 
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